Overactive bladder treatments in early phase clinical trials

Area of Science:

• Urology
• Pharmacology
• Clinical Trials

Background:

• Overactive bladder (OAB) is a prevalent syndrome characterized by urgency, frequency, and nocturia, significantly impacting quality of life.
• Current OAB treatments, primarily antimuscarinic drugs, face challenges with low patient compliance due to side effects.
• The multifactorial pathophysiology of OAB necessitates the development of novel therapeutic agents.

Purpose of the Study:

• To review investigational drugs for overactive bladder (OAB) in preclinical and early-stage clinical trials.
• To highlight the need for new OAB treatments with improved efficacy and tolerability compared to existing antimuscarinic therapies.

Main Methods:

• Literature review of preclinical and Phase I/II clinical trial data for novel OAB therapeutics.
• Analysis of drug targets within the detrusor muscle and neural systems relevant to OAB pathophysiology.

Main Results:

• Several novel molecular targets are under investigation for OAB treatment.
• Early-stage research is exploring drugs with mechanisms of action distinct from antimuscarinics.
• The review covers drugs in investigational preclinical and early-stage (Phase I and II) clinical trials.

Conclusions:

• There is a significant unmet need for OAB treatments with better efficacy and patient acceptance.
• Investigational drugs targeting novel pathways show promise for more effective and tolerable OAB management.
• Continued research into new molecular targets is crucial for advancing OAB therapy.